Introduction
============

Crohn's disease (CD) is an idiopathic inflammatory disorder affecting both small and large intestines. Transmural inflammation with noncaseating granulomas, and inflammation-related fibrosis with marked smooth muscle cell (SMC) proliferation are histological features of this inflammatory bowel disease, and contribute to the development of its characteristic complications such as fistulas and strictures \[[@B1], [@B2]\]. Despite recent extensive investigations of patients and through the usage of animal models, the precise pathological mechanisms of the abnormal inflammatory responses remain to be elucidated \[[@B1], [@B3]\].

Endothelin-1 (ET-1) is a potent vasoconstrictor, and has a mitogenic effect on SMCs \[[@B4], [@B5]\]. Because the proliferation of vascular intimal SMCs is an essential process for atherogenesis \[[@B6], [@B7]\], ET-1 has been considered to play a pathogenic role in the development of atherosclerosis \[[@B8], [@B9]\]. In addition to atherosclerosis, ET-1 has been considered as a possible pathological factor in various inflammatory disorders, including CD \[[@B10]--[@B13]\].

ET-1 can be generated locally by the cleavage of its propeptide, big ET-1, by endothelin-converting enzyme (ECE) \[[@B14]\]. The biological actions of ET-1 are mediated by its specific receptors, endothelin type A receptor (ET~A~) and endothelin type B receptor (ET~B~) \[[@B15]\]. Expressions of these ET system components during inflammatory and wound healing processes have been reported and its significance on the disease processes has been investigated \[[@B9], [@B11], [@B16]\]. Previous studies demonstrated the increase of ET-1 in sera and colonic tissues of patients with CD \[[@B12], [@B13]\]. However, the expression of ECE in affected intestinal tissues of CD has not been studied, and the precise roles of ET~A~ and ET~B~ receptors in the inflammatory and fibrogenic processes of CD remain to be elucidated.

In the present study, we immunohistochemically investigated the expressions of these ET system components, ECE, ET~A~ and ET~B~, in affected human intestinal tissues of CD.

Materials and Methods
=====================

Colonic tissue specimens
------------------------

Eighteen intestinal tissue specimens were sampled from patients with CD \[mean age (yr), 31 ± 6 (±SD); 15 men and 3 women\] by surgery. Reasons for the surgical resections were intestinal strictures (n = 14), fistulas (n = 3) and abscess (n = 1). Normal colonic tissues as controls were obtained from 12 patients \[mean age (yr), 60 ± 7 (±SD); 9 men and 3 women\] having surgery for benign or malignant colonic tumors. Informed consent was obtained from every patient, and the Ethics Committee of Osaka City University Hospital approved this study.

Each colonic tissue specimen was immediately snap-frozen after sampling and stored at −80°C. The frozen samples were subsequently sectioned serially at 6-µm thickness and fixed in acetone. Every first section was stained with hematoxylin and eosin; the other sections were used for the following immunohistochemical analysis.

Immunohistochemistry
--------------------

*Single staining*---The sources and specificity of all antibodies used in the present immunohistochemical study are listed in Table [1](#T1){ref-type="table"}. For the analysis of the expressions of the ET system components in normal and diseased colonic tissues, we used specific anti-ECE antibody (developed by one of us), and anti-ET~A~ and anti-ET~B~ antibodies (kindly provided by Novartis Pharma K.K., Tsukuba Research Institute, Tsukuba, Japan) as primary antibodies \[[@B17], [@B18]\]. Sections were incubated with one of these primary antibodies at 4°C overnight or for one hour at room temperature, and then subjected to a three-step staining procedure using the streptavidin-biotin complex method. Visualization was performed by horseradish peroxidase-based colorimetric reaction with 3-amino-9-ethylcarbazole (10 minutes, room temperature), and the sections were faintly counterstained with hematoxylin. The specificity and results obtained with the primary antibodies were checked by omission of the antibodies and use of a non-immune mouse IgG antibody (Dako Cytomation, Glostrup, Denmark) as a negative control.

*Double immunostaining*---To identify cell types that express the ET receptors (ET~A~ and ET~B~), double immunostainings for ET receptors and SMCs or macrophages were performed according to the method previously reported with minor procedural modifications \[[@B19]\]. Alkaline phosphatase was visualized with fast blue BB (blue: SMC and macrophage) and peroxidase with 3-amino-9-ethylcarbazole (red: ET receptors).

Results
=======

Normal colonic tissues
----------------------

Normal colonic tissues histologically demonstrated no fibrotic and no inflammatory changes. Expressions of ECE, ET~A~ and ET~B~ were seen mainly in the muscular layers and vasculatures (Fig. [1](#F1){ref-type="fig"}). Vascular SMCs were positive for ECE, ET~A~ and ET~B~ (Fig. [2](#F2){ref-type="fig"}). ET~A~ immunoreactivity in vascular SMCs was stronger than ET~B~. Of these ET system components, only ECE was detected in endothelial cells (Fig. [2](#F2){ref-type="fig"}).

Colonic tissues of CD
---------------------

In diseased intestinal tissues of CD, marked proliferation and accumulation of SMCs was frequently seen in the submucosa, in association with inflammatory infiltration and fibrotic tissue reaction. In addition to original SMC tissue components including the muscular layers and vessels, the proliferated SMCs in the submucosa were distinctly positive for the ET system components, ECE, ET~A~ and ET~B~ (Fig. [3](#F3){ref-type="fig"}). In these proliferated SMCs, ET~A~ immunoreactivity was relatively weak compared to ET~B~. In contrast, as seen in normal colonic tissues, expression of ET~A~ in the vascular SMCs was stronger than that of ET~B~ (Fig. [3](#F3){ref-type="fig"}). Macrophages accumulated in the active inflammatory lesions also showed strong expressions of ECE, ET~A~, and ET~B~ (Fig. [4](#F4){ref-type="fig"}). Inflammation associated neovascularization was seen in the lesions, and the newly formed vessels were invariably positive for the ET system components (Fig. [4](#F4){ref-type="fig"}). While ECE expression was confirmed in the endothelial cells, as well as the SMCs, of the newly formed vessels, ET~B~ expression could not be detected in the endothelial cells.

Discussion
==========

This is the first immunohistochemical study based on frozen human colonic sections, that disclosed enhanced expressions of the ET system components, ECE, ET~A~ and ET~B~, in inflammatory and fibrotic lesions of CD. The finding strongly suggests that these ET system components are collectively involved in inflammatory and fibrogenic processes of CD.

ET-1 is a vasoconstrictor peptide that contributes not only to the regulation of vascular tone but also to the repair / fibrogenic processes after tissue injury \[[@B11], [@B16]\]. In addition to cardiovascular system, ET-1 acts on various normal or diseased organs/tissues \[[@B8]--[@B13], [@B16], [@B20]--[@B22]\]. Inagaki *et al.* \[[@B21]\] and Egidy *et al.* \[[@B22]\] reported the immunolocalization of ET system components in human normal colonic tissues and suggested implication of the ET system in physiological functions of human colons. Moreover, the ET system seems to be involved in human colonic diseases, including congenital, neoplastic and inflammatory disorders \[[@B12], [@B13], [@B23]--[@B27]\]. CD has also been recognized as one of such colonic diseases, in which the ET system potentially plays a pathogenic role. In fact, ET-1 levels in both plasma and colonic tissues were increased in patients with CD compared to normal subjects \[[@B12], [@B13]\]. However, no study has revealed expression patterns of the ET system components other than ET-1 in human colonic tissues of CD.

ECE is a final key enzyme in the synthesis of ET-1, and regulates the local ET-1 production \[[@B14]\]. The present immunohistochemical investigation revealed increased ECE expression in inflammatory and fibrotic foci in colonic tissues of patients with CD. The finding can provide a likely explanation for the results of prior studies that showed increased ET-1 in CD patients \[[@B12], [@B13]\]. ECE expression was observed in accumulated macrophages and in proliferated SMCs, both of which are chief effector cells of inflammatory and fibrogenic tissue reactions. Hence, upregulation of ET-1 production by ECE may be an essential process in the development and progression of colonic lesions in CD.

The biological effects of ET-1 are expressed via binding to its specific receptors, ET~A~ and ET~B~ \[[@B15]\]. It had been recognized that the vasoconstrictive and mitogenic properties of ET-1 were mediated mainly by ET~A~ \[[@B28], [@B29]\]. Because ET-1 binding to ET~B~ stimulates the release of nitric oxide from endothelial cells, it has been believed that ET~B~ antagonizes ET~A~-mediated ET-1 function and therefore induces vasodilatation \[[@B30]\]. However, accumulating evidence has recently shown that ET~B~ also contribute to the vasoconstrictive and mitogenic reactions \[[@B11], [@B16], [@B31]\]. We found that both ET~A~ and ET~B~ expressions were enhanced in inflamed and fibrotic colonic lesions of CD. Especially in the fibroproliferative foci in the submucosa, ET~B~ was a dominant ET receptor that was expressed in the proliferated SMCs. ET~B~-mediated nitric oxide production from endothelial cells was thought to be absent in the affected colonic tissues because ET~B~ was not detected in the endothelial cells. The findings could be interpreted that both ET~A~- and ET~B~-mediated ET-1 actions might contribute to develop the inflammation-related fibrosis and SMC proliferation, which is a histological hallmark of intestinal strictures in CD \[[@B2]\].

The precise pathway of the development of CD is still obscure. The results of the present study suggest at least that the ET system plays a pathogenic role in the development of CD and in its characteristic and serious complication, intestinal strictures. Increased ET-1 in the inflamed colonic tissues may induce hypercontraction of the muscular layers and the proliferated SMCs in the submucosa and may worsen the strictures. These mean potential efficacy of ET antagonists in prevention of the disease progression and the complication. Bosentan, a dual ET receptors (ET~A~ and ET~B~) blockade \[[@B31], [@B32]\], may be applicable for the treatment of CD patients and may introduce favorable outcomes in the prevention and resolution of intestinal strictures.

In conclusion, the present study demonstrated the enhanced expressions of ECE, ET~A~ and ET~B~ in affected human colonic tissues of CD. These results strongly suggest that the ET system play a pathogenic role in inflammatory and fibrogenic processes of CD. Administration of ET antagonist may improve the prognosis of patients with CD.
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![Expression of the ET system in normal colonic tissue. (A) Immunostaining for SMCs (1A4). (B--D) Immunostaining for ECE (B), ET~A~ (C) and ET~B~ (D). Main expression sites of these ET system components are muscular layers and vasculatures. Original magnification: A--D, ×30.](jcbn2008018f01){#F1}

![Expression of the ET system in a vessel in normal colonic tissue. (A) Immunostaining for endothelial cell marker, CD31. (B--D) Immunostaining for the ET system components; ECE (B), ET~A~ (C) and ET~B~ (D). Vascular SMCs are positive for all these ET system components. Of these ET system components, only ECE is detectable in endothelial cells (B; arrow). Original magnification: A--D, ×400.](jcbn2008018f02){#F2}

![Expression of the ET system in colonic tissues of CD. (A) Immunostaining for SMCs (1A4). Marked SMC proliferation and accumulation are seen in the submucosa (asterisk). (B--D) Immunostaining for the ET system components; ECE (B), ET~A~ (C) and ET~B~ (D). In addition to SMCs of the muscular layers and the vessels, the proliferated SMCs in the submucosa are positive for all these ET system components. ET~A~ immunoreactivity in these proliferated SMCs is relatively weak. (E, F) Double immunolabeling for ET~A~ (red)/SMC (1A4; blue) (E), and ET~B~ (red)/SMC (1A4; blue) (F). ET~A~ immunoreactivity of the proliferated SMCs is weaker than ET~B~ immunoreactivity (arrows), and conversely, ET~A~ immunoreactivity of the vascular SMCs is stronger than that of ET~B~ immunoreactivity (arrowhead). Original magnification: A--D, ×20; E and F, ×100.](jcbn2008018f03){#F3}

![Expression of the ET system in an active inflammatory lesion in CD. (A) Immunostaining for macrophage marker, CD68. Abundant macrophages are accumulated in the lesion. (B--D) Immunostaining for the ET system components; ECE (B), ET~A~ (C) and ET~B~ (D). In the lesion with marked macrophage accumulation, enhanced expressions of these ET system components are seen (B--D). (E, F) Double immunolabeling for ET~A~ (red)/macrophage (CD68; blue) (E), and ET~B~ (red)/macrophage (CD68; blue) (F). Many macrophages are positive for ET~A~ and/or ET~B~. Original magnification: A--D, ×90; E and F, ×150.](jcbn2008018f04){#F4}

###### 

Primary antibodies used in the present immunohistochemical study

  Designation   Clone or catalog number   Cell identified     Source                        Dilution
  ------------- ------------------------- ------------------- ----------------------------- ----------
  ECE           AEC32-236                 ---                 Shimada *et al.* \[[@B17]\]   1:200
  ET~A~         ---                       ---                 Sasaki *et al.* \[[@B18]\]    1:500
  ET~B~         ---                       ---                 Sasaki *et al.* \[[@B18]\]    1:500
  α-SMC actin   1A4                       SMCs                Dako                          1:200
  CD68          EBM11                     Macrophages         Dako                          1:200
  CD31          JC70A                     Endothelial cells   Dako                          1:100

ECE, endothelin-converting enzyme; ET~A~, endothelin type A receptor; ET~B~, endothelin type B receptor; SMC, smooth muscle cell; Dako, Dako Cytomation (Glostrup, Denmark)
